In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium

Gábor Zsóri, Dóra Illés, Emese Ivány, Klára Kosár, Gábor Holzinger, Máté Tajti, Eszter Pálinkás, Géza Szabovik, András Nagy, András Palkó, L. Czakó

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Nonalcoholic fatty pancreas and liver disease (NAFPD and NAFLD) and pericardial adipose tissue (PAT) are often associated with type 2 diabetes mellitus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, PAT size, and the effect of metformin treatment on NAFLD, NAFPD, and PAT in new-onset T2DM (NODM). Methods: Seventeen patients with NODM and 10 subjects used as a control group were involved in the study. Computed tomography (CT) and laboratory tests were performed before the beginning of metformin therapy and 4 months afterward. PAT and the amount of fat in the pancreas and liver were determined by X-ray attenuation during unenhanced CT examination and compared with the values for the control subjects. Results: Metabolic parameters improved significantly after metformin therapy. NAFLD was diagnosed in 64.7% of the patients with NODM and in 10% of the control subjects. The radiation absorption of the liver was significantly lower in the patients with NODM compared with the control group and significantly higher after metformin therapy compared with the baseline values. Only six patients (35.3%) had NAFLD after metformin therapy. NAFPD was diagnosed in 82.3% of the patients with NODM and in 20% of the control subjects. The radiation absorption of the pancreas was significantly lower in the patients with NODM compared with the control group but did not change significantly after treatment. PAT size was significantly larger in the patients with NODM and did not change significantly after metformin treatment. Conclusions: NAFLD, NAFPD, and increased PAT were detected in the majority of patients with NODM. Metformin therapy decreased the amount of fat in the liver in parallel with an improvement in the metabolic parameters and may, thus, be beneficial for preventing the late consequences of NAFLD.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalMetabolic syndrome and related disorders
Volume17
Issue number5
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Metformin
Pericardium
Pancreas
Diabetes Mellitus
Fats
Adipose Tissue
Liver
Therapeutics
Type 2 Diabetes Mellitus
Control Groups
Tomography
Non-alcoholic Fatty Liver Disease
X-Rays
Incidence

Keywords

  • metformin
  • nonalcoholic fatty liver disease
  • nonalcoholic fatty pancreas disease
  • pericardial adipose tissue
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. / Zsóri, Gábor; Illés, Dóra; Ivány, Emese; Kosár, Klára; Holzinger, Gábor; Tajti, Máté; Pálinkás, Eszter; Szabovik, Géza; Nagy, András; Palkó, András; Czakó, L.

In: Metabolic syndrome and related disorders, Vol. 17, No. 5, 01.06.2019, p. 289-295.

Research output: Contribution to journalArticle

Zsóri, G, Illés, D, Ivány, E, Kosár, K, Holzinger, G, Tajti, M, Pálinkás, E, Szabovik, G, Nagy, A, Palkó, A & Czakó, L 2019, 'In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium', Metabolic syndrome and related disorders, vol. 17, no. 5, pp. 289-295. https://doi.org/10.1089/met.2018.0086
Zsóri, Gábor ; Illés, Dóra ; Ivány, Emese ; Kosár, Klára ; Holzinger, Gábor ; Tajti, Máté ; Pálinkás, Eszter ; Szabovik, Géza ; Nagy, András ; Palkó, András ; Czakó, L. / In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. In: Metabolic syndrome and related disorders. 2019 ; Vol. 17, No. 5. pp. 289-295.
@article{1106937a7be8405ebf8c48beba649f48,
title = "In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium",
abstract = "Background: Nonalcoholic fatty pancreas and liver disease (NAFPD and NAFLD) and pericardial adipose tissue (PAT) are often associated with type 2 diabetes mellitus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, PAT size, and the effect of metformin treatment on NAFLD, NAFPD, and PAT in new-onset T2DM (NODM). Methods: Seventeen patients with NODM and 10 subjects used as a control group were involved in the study. Computed tomography (CT) and laboratory tests were performed before the beginning of metformin therapy and 4 months afterward. PAT and the amount of fat in the pancreas and liver were determined by X-ray attenuation during unenhanced CT examination and compared with the values for the control subjects. Results: Metabolic parameters improved significantly after metformin therapy. NAFLD was diagnosed in 64.7{\%} of the patients with NODM and in 10{\%} of the control subjects. The radiation absorption of the liver was significantly lower in the patients with NODM compared with the control group and significantly higher after metformin therapy compared with the baseline values. Only six patients (35.3{\%}) had NAFLD after metformin therapy. NAFPD was diagnosed in 82.3{\%} of the patients with NODM and in 20{\%} of the control subjects. The radiation absorption of the pancreas was significantly lower in the patients with NODM compared with the control group but did not change significantly after treatment. PAT size was significantly larger in the patients with NODM and did not change significantly after metformin treatment. Conclusions: NAFLD, NAFPD, and increased PAT were detected in the majority of patients with NODM. Metformin therapy decreased the amount of fat in the liver in parallel with an improvement in the metabolic parameters and may, thus, be beneficial for preventing the late consequences of NAFLD.",
keywords = "metformin, nonalcoholic fatty liver disease, nonalcoholic fatty pancreas disease, pericardial adipose tissue, type 2 diabetes mellitus",
author = "G{\'a}bor Zs{\'o}ri and D{\'o}ra Ill{\'e}s and Emese Iv{\'a}ny and Kl{\'a}ra Kos{\'a}r and G{\'a}bor Holzinger and M{\'a}t{\'e} Tajti and Eszter P{\'a}link{\'a}s and G{\'e}za Szabovik and Andr{\'a}s Nagy and Andr{\'a}s Palk{\'o} and L. Czak{\'o}",
year = "2019",
month = "6",
day = "1",
doi = "10.1089/met.2018.0086",
language = "English",
volume = "17",
pages = "289--295",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium

AU - Zsóri, Gábor

AU - Illés, Dóra

AU - Ivány, Emese

AU - Kosár, Klára

AU - Holzinger, Gábor

AU - Tajti, Máté

AU - Pálinkás, Eszter

AU - Szabovik, Géza

AU - Nagy, András

AU - Palkó, András

AU - Czakó, L.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Nonalcoholic fatty pancreas and liver disease (NAFPD and NAFLD) and pericardial adipose tissue (PAT) are often associated with type 2 diabetes mellitus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, PAT size, and the effect of metformin treatment on NAFLD, NAFPD, and PAT in new-onset T2DM (NODM). Methods: Seventeen patients with NODM and 10 subjects used as a control group were involved in the study. Computed tomography (CT) and laboratory tests were performed before the beginning of metformin therapy and 4 months afterward. PAT and the amount of fat in the pancreas and liver were determined by X-ray attenuation during unenhanced CT examination and compared with the values for the control subjects. Results: Metabolic parameters improved significantly after metformin therapy. NAFLD was diagnosed in 64.7% of the patients with NODM and in 10% of the control subjects. The radiation absorption of the liver was significantly lower in the patients with NODM compared with the control group and significantly higher after metformin therapy compared with the baseline values. Only six patients (35.3%) had NAFLD after metformin therapy. NAFPD was diagnosed in 82.3% of the patients with NODM and in 20% of the control subjects. The radiation absorption of the pancreas was significantly lower in the patients with NODM compared with the control group but did not change significantly after treatment. PAT size was significantly larger in the patients with NODM and did not change significantly after metformin treatment. Conclusions: NAFLD, NAFPD, and increased PAT were detected in the majority of patients with NODM. Metformin therapy decreased the amount of fat in the liver in parallel with an improvement in the metabolic parameters and may, thus, be beneficial for preventing the late consequences of NAFLD.

AB - Background: Nonalcoholic fatty pancreas and liver disease (NAFPD and NAFLD) and pericardial adipose tissue (PAT) are often associated with type 2 diabetes mellitus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, PAT size, and the effect of metformin treatment on NAFLD, NAFPD, and PAT in new-onset T2DM (NODM). Methods: Seventeen patients with NODM and 10 subjects used as a control group were involved in the study. Computed tomography (CT) and laboratory tests were performed before the beginning of metformin therapy and 4 months afterward. PAT and the amount of fat in the pancreas and liver were determined by X-ray attenuation during unenhanced CT examination and compared with the values for the control subjects. Results: Metabolic parameters improved significantly after metformin therapy. NAFLD was diagnosed in 64.7% of the patients with NODM and in 10% of the control subjects. The radiation absorption of the liver was significantly lower in the patients with NODM compared with the control group and significantly higher after metformin therapy compared with the baseline values. Only six patients (35.3%) had NAFLD after metformin therapy. NAFPD was diagnosed in 82.3% of the patients with NODM and in 20% of the control subjects. The radiation absorption of the pancreas was significantly lower in the patients with NODM compared with the control group but did not change significantly after treatment. PAT size was significantly larger in the patients with NODM and did not change significantly after metformin treatment. Conclusions: NAFLD, NAFPD, and increased PAT were detected in the majority of patients with NODM. Metformin therapy decreased the amount of fat in the liver in parallel with an improvement in the metabolic parameters and may, thus, be beneficial for preventing the late consequences of NAFLD.

KW - metformin

KW - nonalcoholic fatty liver disease

KW - nonalcoholic fatty pancreas disease

KW - pericardial adipose tissue

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85067371843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067371843&partnerID=8YFLogxK

U2 - 10.1089/met.2018.0086

DO - 10.1089/met.2018.0086

M3 - Article

C2 - 31013454

AN - SCOPUS:85067371843

VL - 17

SP - 289

EP - 295

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 5

ER -